BioSpace News Archive

Business

BioSpace Movers & Shakers, Aug. 23

Biopharma companies strengthen their senior leadership teams and boards of directors with this week’s appointments.

August 22, 2019

·

5 min read

·

Alex Keown

denovoMATRIX Introduces Ready-To-Use, Chemically Defined Coated Cell Cultureware for Serum-Free hMSC Expansion

Due to their high accessibility and extensive beneficial properties, human Mesenchymal Stem Cells offer exciting promises in a plethora of applications in regenerative medicine, particularly in cell-based therapies.

August 22, 2019

·

1 min read

Biocon’s Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification, Provides Fillip to its Capacity

Biocon Ltd, Asia’s premier biopharmaceuticals company, Biocon Ltd announced that it’s subsidiary in Malaysia, Biocon Sdn.

August 22, 2019

·

3 min read

Drug Development

Janssen Reports Positive Top-line Phase 3 Study Results of Investigational, Long-acting Injectable HIV Treatment Regimen Administered Every Two Months

ATLAS-2M study met its primary objective of demonstrating similar efficacy of long-acting rilpivirine and cabotegravir administered every two months compared to monthly administration

August 22, 2019

·

5 min read

Business

AGS Health appoints Patrice Wolfe as new CEO

Patrice has in-depth expertise in building and scaling healthcare platforms

August 22, 2019

·

2 min read

Business

BioInvent: Interim Report January 1 - June 30, 2019

We are executing according to plan. Our lead candidate BI-1206 has shown encouraging initial data in hematological cancers, and has now also entered clinical trials in solid cancer

August 22, 2019

·

4 min read

Policy

Sobi has Entered Into Agreement to Sell Priority Review Voucher

Swedish Orphan Biovitrum AB has entered into an agreement to sell a US Food and Drug Administration Priority Review Voucher to AstraZeneca for a total cash consideration of USD 95 M.

August 22, 2019

·

1 min read

Drug Development

ViiV Healthcare Reports Positive Phase III Study Results of Investigational, Long-acting, Injectable HIV-Treatment Regimen Administered Every Two Months

ATLAS-2M study met its primary endpoint, showing similar efficacy of cabotegravir and rilpivirine administered every eight weeks compared to four-week administration

August 22, 2019

·

5 min read

Business

Nordic Nanovector ASA - Results for the Second Quarter and First Half 2019

Nordic Nanovector ASA announces its results for the second quarter and first half 2019.

August 22, 2019

·

8 min read

FDA

Miracor Medical Granted FDA Breakthrough Device Designation for the PiCSO Impulse System

Miracor Medical SA has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration for its PiCSO® Impulse System for treatment of STEMI patients.

August 22, 2019

·

3 min read